Canada's Generex Biotechnology Corp says that the Mexican Institute of Industrial Property has granted it a patent titled: "Pharmaceutical Compositions for Buccal and Pulmonary Application." The document covers claims to the composition, process and methodologies for the delivery of macromolecules via the buccal cavity of the mouth.
Generex added that, following the award, it now holds 78 patents worldwide relating to the technology, and has a further 62 applications pending in various jurisdictions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze